Log in

Company updateCNBC-TV18

Biocon shares gain after US FDA approves cancer drug biosimilar

Positive+403 sources

GreyOak summary

Biocon shares rose following US FDA approval for Pebrilzo, a biosimilar to Perjeta for HER2-positive breast cancer. This marks the company's fifth oncology biosimilar approval. The drug is expected to enter the US market in the third quarter of 2028 under a licensing agreement with Genentech.

What it affects

  • BioconBIOCONPositive +40

    Shares gained after US FDA approval for Pebrilzo.Rolling sentiment Positive +18

Source

Read the original at CNBC-TV18

More Biocon news

No other recent stories about Biocon.

All Biocon news →